Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has shared an update.
Neuren Pharmaceuticals Limited has announced an update regarding its ongoing buy-back of ordinary fully paid securities, with a total of 48,819 securities bought back on the previous day, adding to the 4,027,331 securities bought back before that. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value, reflecting a proactive approach in its financial operations.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$31.40 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurological disorders. The company is known for its work on treatments for conditions such as Rett syndrome and Fragile X syndrome, aiming to address unmet medical needs in these areas.
YTD Price Performance: 4.80%
Average Trading Volume: 713,249
Technical Sentiment Signal: Hold
Current Market Cap: A$1.66B
Find detailed analytics on NEU stock on TipRanks’ Stock Analysis page.